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CD248 with antibodies as a diagnostic imaging agent and 
as a therapeutic antibody in an early clinical trial. The 
optimal approach for generating effective DNA-based 
cancer vaccines for several tumor types may be a combi-
natorial approach that enhances immunogenicity such as 
combination with chemotherapy. Additional combination 
approaches are discussed and include those that alleviate 
the immunosuppressive tumor microenvironment induced 
by myeloid-derived suppressor cells and T regulatory cells. 
Targeting the tumor vasculature by CD248-based immu-
nological modalities expands the armamentarium against 
cancer.
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Abbreviations
ACT  Adoptive cell therapy
ALL  Acute lymphocytic leukemia
APC  Antigen-presenting cells
bFGF  Basic fibroblast growth factor
CAIX  Carbonic anhydrase IX
CAR  Chimeric antigen receptor
CLL  Chronic lymphocytic leukemia
CTL  Cytotoxic T lymphocytes
CXCL  Chemokine (C-X-C motif) ligand
DC  Dendritic cells
E2  17β-estradiol
EC  Endothelial cells
EPC  Endothelial progenitor cells
G-CSF  Granulocyte colony-stimulating factor
HGF  Hepatocyte growth factor
IFN  Interferon
IL  Interleukin
IMG  Intussusceptive microvascular growth
Abstract Targeting the tumor vasculature with anti-
angiogenesis modalities is a bona fide validated approach 
that has complemented cancer treatment paradigms. Tumor 
vasculature antigens (TVA) can be immunologically tar-
geted and offers multiple theoretical advantages that may 
enhance existing strategies against cancer. We focused on 
tumor endothelial marker 1 (TEM1/CD248) as a model 
TVA since it is broadly expressed on many different can-
cers. Our DNA-based vaccine approach demonstrated that 
CD248 can be effectively targeted immunologically; anti-
tumor responses were generated in several mouse models; 
and CD8+/CD4+ T cell responses were elicited against 
peptides derived from CD248 protein. Our work supports 
our contention that CD248 is a novel immunotherapeu-
tic target for cancer treatment and highlights the efficient, 
safe and translatable use of DNA-based immunotherapy. 
We next briefly highlight ongoing investigations targeting 
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MDSC  Myeloid-derived suppressor cells
MHC  Major histocompatibility complex
MMP  Matrix metalloproteinases
PDGF  Platelet-derived growth factor
scFv  Single-chain antibody
TAA  Tumor-associated antigen
TCR  T cell receptor
TEM  Tumor endothelial marker
TGF  Transforming growth factor
TNF  Tumor necrosis factor
Treg  T regulatory lymphocytes
TT  Tetanus toxoid
TVA  Tumor vasculature antigen
VDA  Vascular-disrupting agents
VEGF  Vascular endothelial growth factor
VEGFR  Vascular endothelial growth factor receptor
Introduction
Vasculature formation depends on the process of angiogen-
esis, which is responsible for the remodeling and expan-
sion of the existing vasculature network and vasculogen-
esis, a process whereby endothelial precursor cells (EPC) 
migrate and differentiate in response to local signals (such 
as growth factors from stroma and extracellular matrix) to 
form new blood vessels. Vasculogenesis is a fundamental 
process during embryogenesis and in adults takes place 
during tumor growth, following trauma and in endometri-
osis [1]. In normal tissues, angiogenesis is a tightly regu-
lated physiological process that comprises two different 
mechanisms: endothelial cells (EC) sprouting and intussus-
ceptive microvascular growth (IMG), which are regulated 
by several endogenous activator (pro-angiogenic factors) 
and inactivator (anti-angiogenic factors) molecules. Pro-
angiogenic factors include vascular endothelial growth 
factor (VEGF), platelet-derived growth factor (PDGF), 
hepatocyte growth factor (HGF), basic fibroblast growth 
factor (bFGF), matrix metalloproteinases (MMP), trans-
forming growth factor (TGF)-β and angiopoietins among 
others. Anti-angiogenic factors include interferon (IFN)-γ, 
CXCL9, CXCL10, thrombospondin 1, endostatin and angi-
ostatin [2].
For cancer progression, angiogenesis is a necessary step 
in the uncontrolled proliferation, invasion, and metastatic 
dissemination of tumor cells, involving the formation and 
remodeling of new vessels to “feed” the tumor and promote 
its progression. Cancer angiogenesis begins when tumor 
nodules reach dimensions over a few millimeters, and nutri-
ent/oxygen diffusion is no longer sufficient to sustain both 
the physiological cell cycle and basic cell metabolism. In 
response to these unfavorable conditions, cancer cells pro-
duce pro-angiogenic signals that are able to activate resting 
EC and stromal cells. The activated EC acquire the ability 
to proliferate, migrate, differentiate and remodel adjacent 
extracellular matrix in association with pericytes to stabi-
lize the new blood vessels [3].
Anti-vascular strategies are mainly classified into two 
groups: anti-angiogenic and vascular-disrupting thera-
pies. The VEGF–VEGF receptor (VEGFR) signaling axis 
has emerged as one of the most promising angiogenic tar-
gets because of its central role in tumor angiogenesis and 
growth. VEGFA (commonly referred to as “VEGF”) has 
been identified as the predominant pro-angiogenic growth 
factor expressed by tumor cells and binds both VEGFR1 
and VEGFR2 [4, 5]. Angiogenesis has become an accepted 
target for anticancer therapy since 2004 when bevacizumab, 
a VEGF-binding antibody, became the first angiogenesis 
inhibitor to be approved in the USA for the treatment of 
several metastatic cancer types (as a single or in combi-
nation with different cytotoxic chemotherapy) including 
colorectal cancer, non-squamous non-small cell lung can-
cer, renal cell carcinoma, cervical cancer, ovarian cancer 
and as a monotherapy for glioblastoma (Avastin Prescrib-
ing Information, 2015). Major side effects of bevacizumab 
result from the undesirable targeting of normal vascula-
ture including gastrointestinal perforation, wound heal-
ing complications, hemorrhaging and effects on reproduc-
tion (Avastin Prescribing Information, 2015). The VEGFR 
signaling pathway as well as other angiogenic receptors 
(EGFR, PDGFR, FGFR) has also been targeted with the 
development of small molecule tyrosine kinase inhibitors 
such as vandetanib, cabozantinib, sorafenib, ponatinib and 
lenvatinib [6]. Vascular-disrupting agents (VDA), a rela-
tively new class of drugs in clinical development, target 
and destroy preexisting tumor vessels, resulting in tumor 
cell death from ischemia and necrosis [7]. Preclinical data 
using VDA have confirmed the extraordinary potential of 
this approach to control tumor growth by inducing mas-
sive necrosis of cancer cells. VDA small molecules, such as 
tubulin-depolymerizing agents and flavonoids, have already 
produced promising preclinical results, although they lack 
robust specificity and induce neurological and cardiovascu-
lar side effects as observed in a phase I clinical trial [8]. 
The development of novel, effective and safe VDA for can-
cer therapy has been currently hindered by both the paucity 
of selective targets for different tumors and the lack of rea-
gents with optimal affinity.
In the last several decades, anticancer vaccination strate-
gies have been developed by different approaches prefer-
entially based on targeting tumor cells expressing tumor-
associated antigens (TAA) [9]; however, tumor cells are 
genetically unstable and when immune pressure is applied, 
can rapidly give rise to antigen escape variants, resulting 
in treatment failures. Development and delivery of immu-
notherapy directed against tumor vasculature antigens 
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(TVA) offer multiple theoretical advantages: (1) TVA are 
overexpressed on cancers of different histological types, 
whereas they are generally absent or poorly expressed on 
most normal tissue; (2) the tumor vasculature and stroma 
are genetically stable as compared to tumor cells, which 
can minimize escape variants [10, 11]; (3) TVA-targeting 
therapies can be broadly applicable to different cancers 
[12]; (4) TVA targeting is endowed with powerful effector 
lymphocytes that can persist in tumor-bearing hosts, leav-
ing a long-lasting memory response that protects the host 
against tumor recurrence; (5) TVA-targeting efficacy can be 
enhanced in combination with different pharmacological/
immunological strategies as we describe in the last section. 
In this review, we describe recent findings on the applica-
tion of targeting the tumor vasculature with a CD248-spe-
cific DNA vaccine, highlighting its rationale, its therapeutic 
effectiveness and latest developments as well as potential 
future areas of clinical improvement.
CD248 background
As reported by Brad St. Croix et al. [13], colorectal tumor 
endothelium was found to up-regulate several genes com-
pared to the normal intestinal endothelium; nine genes 
were overexpressed up to tenfold in tumor-derived ver-
sus normal-derived endothelium and were dubbed tumor 
endothelial marker (TEM). TEM overexpression in tumor 
vessels was confirmed by reverse transcriptase polymerase 
chain reaction and in situ hybridization [14]. These TEMs 
are found on the cell surface and although are not struc-
turally related (TEM1, 3, 5, 7, 8), they are functionally 
conserved between mouse and human tumor endothelium. 
These two attributes make TEMs attractive candidates for 
immunotherapeutic interventions because these targets are 
directly accessible to the immune cells via the tumor vas-
culature. The most differentially expressed TEM, TEM1 
(CD248) was found to be the same antigen, previously 
dubbed endosialin, a highly sialylated glycoprotein found 
on many different tumor types described first in the Rettig 
seminal paper [15]. Human CD248 mRNA and/or protein 
has been characterized in various human tumor settings 
including colorectal cancer, brain tumors and sarcomas 
[16–18]. CD248 has also been reported to be expressed by 
tumor vessel-associated pericytes [19] and stromal fibro-
blasts [20] on a broad variety of human tumors with dif-
ferent histology but not in normal vessels [21]. Moreover, 
CD248 has also been classified as a marker of tumor ves-
sel-associated pericyte cells and tumor-associated myofi-
broblasts [22] as well as a selective EPC marker [23]. 
Pericytes provide structural support for EC and therefore 
stabilize the vasculature. CD248 plays a role in physiologi-
cal processes such as cell adhesion, neo-angiogenesis, cell 
migration and tissue development [24] and has an essen-
tial role in promoting tumor growth; its overexpression 
negatively correlated with the clinical outcome of cancer 
patients [25]. Using a knockout mouse model for CD248 
expression (Tem1−/− mice), researchers were able to iden-
tify the physiological and biological role of CD248 in pro-
moting tumor progression. Tumor growth was inhibited 
in Tem1−/− mice, and metastatic dissemination was also 
reduced. Normal wound healing was observed in Tem1−/− 
mice compared to wild-type mice [24]. These data suggest 
that targeting CD248 may generate efficient therapeutic 
effects with minimal toxicity.
CD248 targeting by DNA vaccine as a useful 
approach to strike tumor vasculature
To test the hypothesis that CD248 is a suitable candidate 
for cancer immunotherapy, we designed an active immu-
notherapeutic approach based on a DNA-based vaccine in 
conjunction with in vivo gene transfer [26]. To increase the 
immunogenicity of CD248 and break murine tolerance, we 
developed a DNA vaccine based on fusing mouse CD248 
cDNA with the cDNA of the amino terminal domain 
of fragment C of tetanus toxoid (TT). The TT fragment 
DNA was introduced at the 3′ end of the CD248 coding 
sequence, generating the plasmid called pcDNA3.1/TEM1-
TT. The TEM1-TT DNA sequence was codon-optimized to 
increase expression yields up to 100-fold as well as inclu-
sion of CpG motifs which activate TLR9 to increase immu-
nogenicity of the DNA vaccine. As an adjuvant, TT may 
enhance immunogenicity through several mechanisms; the 
whole C fragment of TT activates dendritic cells (DC) to 
secrete cytokines involved in CD4+ T cell activation and 
Th1 polarization, such as interleukin (IL)-12, IL-23 and 
tumor necrosis factor (TNF)-α [27]. In addition, fragment 
C contains universal T helper epitopes (p30, p2), which are 
effective across different major histocompatibility complex 
(MHC) class II haplotypes in mice and humans and elic-
its strong CD4+ T responses [28]. Lastly, electrogene ther-
apy induces local inflammation and promotes a favorable 
microenvironment that is able to stimulate T cell fitness and 
functionality [29].
We have reported that mice vaccinated with TEM1-
TT plasmid vaccine were able to develop T lymphocytes 
with strong reactivity against a CD248-specific peptide; 
vaccinated C57BL/6 mice generated a specific CD8+ T 
cell response toward the TEM1696–710 peptide (GQSQRD-
DRWLLVALL). TEM1-TT-vaccinated BALB/c mice 
responded with elicitation of a CD8+ and a CD4+ T cell 
response against two CD248 peptides: TEM1516–530 
(ITSATHPARSPPYQP) and TEM1511–525 (GHKPGIT-
SATHPARS). Moreover, the identified CD248-derived 
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peptides were able to expand CD248-specific cytotoxic 
T lymphocytes (CTL) in vitro that selectively recognized 
CD248-expressing endothelium immortalized cells such as 
H5V cells. Our data are the first demonstration of CD248 
immunogenicity and establishes a foundation upon which 
to develop selective immunotherapy against this potential 
TVA. TEM1-TT vaccine was able to control in vivo tumor 
progression of different transplantable tumor models by 
both prophylactic and therapeutic immunization [26]. 
The therapeutic effectiveness of our vaccine can be sum-
marized in three parts as schematically shown in Fig. 1. 
Firstly, TEM1-TT vaccine elicits anti-CD248 CTLs that 
specifically attack the tumor vasculature, resulting in sig-
nificant inhibition and ablation of the tumor vasculature 
[26]. The TEM1-TT vaccine modified the tumor vessel 
architecture as demonstrated by reduction of CD31+ EC 
and/or pericytes in the CT26 tumor model. By RNA FISH, 
CD248 mRNA was found to localize with, or to be in close 
juxtaposition to, CD31 mRNA, suggesting that EC and/
or pericytes are expressing CD248 [26]. We also show 
that in TEM1-TT-vaccinated mice, CT26 tumor contained 
CD31+ cells that were also TUNEL positive, suggesting 
that CD31+ EC/pericytes were in an apoptotic state [26]. 
Pericyte coverage on EC provides the structural support for 
the vasculature. Since CD248 is expressed by tumor vessel-
associated pericyte cells [22], TEM1-TT vaccine may also 
target pericytes directly, with subsequent destabilization 
and inhibition of the tumor endothelial cell network. This 
selective inhibition of tumor vascularity was also verified 
by in vivo ultrasound imaging which allowed us to define 
physical vascular parameters of the tumor mass such as the 
perfused tumor area and the red blood cell flux per unit area 
Fig. 1  Proposed mechanism of the therapeutic effectiveness of 
TEM1-TT vaccination. (1) TEM1-TT vaccine stimulates the elicita-
tion and expansion of CD248-specific CTLs. Cytolysis of CD248+ 
tumor-derived EC/pericytes results in blood vessel fenestration induc-
ing vessel collapse as well as difficulty assembling new vasculature. 
(2) The lack of a constant supply of metabolites and oxygen promotes 
a hypoxic tumor microenvironment. This detrimental condition pro-
motes both a tumor cell non-proliferative state and tumor cell apopto-
sis. Tumor apoptosis generates a source of TAA that can be engulfed 
by APC such as DC and macrophages recruited by the inflammation 
near the tumor mass. (3) These APC are able to process and present 
TAA peptide in association with MHC-I molecules. This secondary 
cross-priming event produces the expansion of both specific anti-
TAA CTLs and plasma cell producing anti-TAA antibody. This sec-
ond immune response assists the CD248-specific immune attack to 
control and limit tumor progression
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of tissue. Collectively, our data demonstrate that TEM1-TT 
vaccine functionally destabilizes the tumor vasculature, 
induces vessel collapse, as well as possibly impedes the 
assembly of new vasculature [26].
The second part of our proposed mechanism includes 
the consequences of tumor vessel destruction mediated 
by the TEM1-TT vaccine. We hypothesize that the lack 
of a constant stream of metabolites and oxygen leads to 
an increased hypoxic and inflammatory tumor microen-
vironment that promotes tumor cell death. Tumor cells 
from TEM1-TT-vaccinated mice showed an increase in 
tumor cell apoptosis. We verified that tumor masses iso-
lated from TEM1-TT-vaccinated mice showed higher lev-
els of carbonic anhydrase IX (CAIX), a cellular biomarker 
of hypoxia, which correlated with an elevated presence of 
apoptotic tumor areas. Furthermore, we evaluated tumor 
cells of TEM1-TT-vaccinated mice for Ki67 expression and 
found Ki67 down-regulation, indicating a less proliferative 
state compared to tumor cells from control-treated mice 
(Andrea Facciabene, unpublished results).
The ability of our vaccine to provide a secondary tumor-
specific immune response represents the third and last step 
of the therapeutic effectiveness of TEM1-TT vaccine. All 
of these above events (hypoxia, tumor EC/pericyte apopto-
sis, tumor cells’ proliferative status/apoptosis) can gener-
ate a source of antigenic determinants that can be engulfed 
by antigen-presenting cells (APC) such as DC and mac-
rophages. These APC are able to process specific tumor cell 
antigens by cross-priming, promoting a secondary immune 
response [30] against the tumor-specific antigens. In our 
tumor models, CT26- and TC1-associated tumor apoptotic/
necrotic bodies were processed by APC inducing a second-
ary immune response against specific TAA; the immuno-
dominant antigen of CT26, gp70423–431 (AH1 peptide) is 
derived from viral antigen Gp70 encoded by the genome 
of BALB/c mice [31]. Gp70 is poorly expressed in normal 
tissues [32]; AH1-specific T cells escape negative selection 
that can therefore be activated and expanded by inflamma-
tion associated during tumor progression [33]. In the TC-1 
tumor model, a C57BL/6 epithelial lung tumor, tumorigen-
esis is maintained by the expression of the viral proteins 
E6 and E7 of HPV origin. E7 is recognized by the immune 
system and elicits a selective CTL response against the E7 
immunodominant peptide E749–57 [34]. Our data clearly 
demonstrate that splenocytes from TEM1-TT-vaccinated 
mice contained CD8+ T cell specific immune responses 
against CD248 immunodominant peptide (but not against 
the control CD248 peptide), as well as against the AH1 
epitope in CT26-tumor-bearing mice or E749–57 epitope in 
TC1-tumor-bearing mice [26]. Moreover, the frequency 
of the specific TAA-related immune response correlated 
with the tumor volume, suggesting that the magnitude of 
the secondary immune response was important to control 
tumor progression. The induction of this secondary TAA-
specific anti-tumor response amplifies the magnitude of the 
therapeutic effectiveness of the CD248-targeting strategy.
To define the immune system component (adaptive and/
or humoral) that was responsible for the anti-tumor effects, 
we performed CD3+ T cell adoptive transfer or adoptive 
serum transfer from TEM1-TT-immunized naïve donor 
mice into naïve mice that were irradiated and challenged 
with CT26 tumor and found that CD3+ T cells exclusively 
mediated the anti-tumor effects [26]. To characterize the 
potency of the TEM1-TT vasculature-targeting compo-
nent with the secondary TAA immune response compo-
nent, we performed CD3+ T cell adoptive transfer from 
either TEM1-TT-immunized mice (vaccinated only) donor 
mice or TEM1-TT-immunized tumor-bearing (vaccinated 
followed by tumor challenged) donor mice into recipient 
mice that were challenged with CT26 tumor. Both types of 
adoptively transferred donor cells significantly increased 
the survival of recipient mice once challenged with CT26. 
These data demonstrate the anti-CD248 immune response 
in the recipient mice adoptively transferred with CD3+ T 
cells from vaccinated only donor mice (without concomi-
tant cross-priming and epitope spreading) was sufficiently 
potent to control tumor growth [26]. This observation sug-
gests that the therapeutic ability of TEM1-TT vaccine is 
not secondary to development of an anti-TAA response 
but is solely capable, on its own, to limit tumor progres-
sion. We hypothesize that the anti-CD248 cellular immune 
response is the initial triggering event that generates and 
sustains a secondary TAA cross-priming event, expanding 
TAA tumor-specific cytotoxic CD8+ T cells that control 
tumor growth.
Since neo-angiogenesis is also a physiological process 
that occurs during wound healing and reproduction, we 
investigated whether these two physiological processes 
were negatively affected by the TEM1-TT vaccine. Our 
results demonstrate that CD248 targeting did not mediate 
normal vessel damage in the skin by inducing toxicity dur-
ing wound healing. Moreover, we showed that TEM1-TT 
immunization did not alter the pregnancy success rate, the 
time to gestation, the total litter size and the pup weight at 
birth compared with control immunization; there were also 
no anatomical or histological abnormalities in embryos 
from TEM1-TT- or control-immunized groups during early 
or late gestation. Lastly, our vaccine did not affect normal 
luteogenesis; in fact, TEM1-TT-immunized mice presented 
the same serum levels of 17β-estradiol, progesterone, lute-
inizing hormone and follicle-stimulating hormone during 
their estrus cycle compared to control-vaccinated mice 
[26]. These results are critical to demonstrate that TEM1-
TT vaccine is a safe immunization strategy because it does 
not induce an immune response against physiological neo-
angiogenesis compared with other anti-vascular therapy 
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such as bevacizumab, which is associated with important 
safety concerns, including wound healing [35] and preg-
nancy [36]. Overall, our data demonstrate that targeting the 
vasculature with a TEM1-TT DNA-based vaccine is a safe 
immunotherapeutic approach and further investigations are 
warranted.
Future perspective and potential applications
Identification and characterization of TVA such as CD248 
and other TEM family members have created strong 
rationale and motivation to develop cancer immunother-
apy against the tumor vasculature. The feasibility of this 
approach has been verified by experiments based on the 
use of Tem1−/− mice, where it was demonstrated that the 
genetic ablation of CD248 was not lethal and was associ-
ated with both control of tumor progression, local invasion 
and a reduction of metastases [24]. Our strategy to break 
CD248 self-tolerance using the sequence of modified TT 
adjuvant lays the foundation for developing other potential 
fusion protein constructs using cDNA of CD248 or other 
TEMs in association with the cDNA of either other micro-
bial-derived proteins, such as the heat-labile enterotoxin B 
subunit (LTB) of enterotoxigenic Escherichia coli [37, 38], 
or other immunogenic molecules such as pathogen-asso-
ciated molecular patterns (PAMP) [39]. The therapeutic 
effectiveness of electrogene transfer with the fusion vaccine 
encoding human CD248 (hCD248) cDNA will be tested 
in guiding clinical trials since the safety of DNA-based 
modalities has already been demonstrated [40]. Identifica-
tion of the immunodominant peptide(s) of hCD248 should 
be a source of innovative clinical trials in which patients 
will be treated with new formulations of either emulsion-
ated peptide immunization in which CD248 peptide will be 
injected with effective adjuvants such as montanide [41] or 
CD248 peptide-loaded DC vaccination protocols (Fig. 2). 
The most effective immunotherapy approach today is based 
on adoptive cell therapy (ACT) [42]. To test the potential of 
CD248-specific T cells, we adoptively transferred T cells 
from CD248-immunized mice into tumor-bearing mice 
and clearly demonstrate CD248-specific T cells are capa-
ble to reject established tumors. Engineered high-affinity 
anti-CD248 T cell ACT is a potential innovative approach 
in which the gene sequences of TCR α and β chains can 
be isolated and inserted into a lentiviral/retroviral vector 
carrying a bidirectional promoter capable of robust and 
coordinated expression of the two transgenes. Transduction 
of donor peripheral blood mononucleated cells (PBMC) 
with the lentiviral vector leads to generation of specific 
anti-hCD248-positive T cells. This strategy can over-
come the obstacles of ACT in the clinic including techni-
cal factors limiting the availability of sufficient numbers of 
tumor-specific T cells as well as the availability of an anti-
gen shared by tumors of different histologic patterns and 
conserved during tumor progression [43]. The potential of 
engineered human anti-CD248 T cells for adoptive transfer 
could be useful to treat a broad spectrum of histologically 
different cancers since many tumor types express CD248 to 
varying degrees.
In addition to targeting CD248 with T cell-based immu-
notherapy protocols, other investigators have been devel-
oping both diagnostic and therapeutic antibodies against 
CD248 antigen. Radiolabeled 125I-Fc78 antibody was 
designed and based on a CD248-specific fully human 
single-chain antibody (scFv) 78, shown to bind with high 
affinity to both human and mouse CD248 [44, 45]. An ideal 
antibody-based therapy platform should have an antibody 
that can be used for diagnostic and therapeutic use (thera-
nostic). The diagnostic antibody should be amenable to 
complexing to an imaging agent as well as complexing the 
antibody to a cytotoxic agent. The theranostic potential of 
MORAb-004 as a PET imaging tracer and naked antibody 
therapy for CD248+ tumor has recently been demonstrated 
[46]. (124)I-MORAb-004, a humanized monoclonal anti-
body targeting an extracellular epitope of hCD248, was 
evaluated for its ability to specifically and sensitively detect 
vascular cells expressing hCD248 in vivo [47]. Lastly, 
since CD248 is a cell surface marker, MORAb-004 anti-
body is currently undergoing phase I clinical trials for the 
treatment of patients with various cancers [15, 48]. With 
great enthusiasm, it is possible to use CD248-scFV to cre-
ate chimeric antigen receptor (CAR)-bearing T cells to rec-
ognize hCD248 on endothelial targets in vivo. For exam-
ple, CAR T cells directed against VEGFR have been shown 
to destroy the tumor vasculature and impair tumor growth 
[49]. Strikingly, up to 90 % of acute lymphocytic leukemia 
(ALL) patients and up to 50 % of chronic lymphocytic leu-
kemia (CLL) patients are in durable remission with T cells 
engineered with CARs [50]. All of the aforementioned 
potential immunotherapeutic strategies based on CD248 
targeting are summarized in Fig. 2.
CD248-based immunotherapy in combination with 
chemotherapy can be a suitable approach for translation 
into the clinic. The majority of chemotherapeutic com-
pounds, when used at clinically useful doses, are endowed 
with intrinsic immunosuppressive properties owing to the 
fact that they preferentially kill rapidly proliferating cells. 
However, most of these drugs are able to stimulate the 
immune system against cancer by various different mecha-
nisms: directly activating CD4+, CD8+ or γδ T cells, pro-
moting the production of IL-2, IFN-γ and IL-17, facilitating 
the maturation or activation of DC, inhibiting or depleting 
immunosuppressive cell subsets, triggering immunogenic 
cell death of tumor cells, up-regulating MHC-I molecules 
on cancer cells, increasing the permeability of tumor cells 
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to granzyme B and inhibiting immunosuppressive cytokine 
release such as IL-10 or up-regulating the expression of 
type I IFN [51]. These chemotherapy immune-modulating 
properties can be used to improve the therapeutic efficacy 
of CD248-based immunization both in preclinical and in 
clinical settings as previously described for different tumor 
antigens [52]. CD248-based immunotherapy might be 
combined with other anti-vasculature agents such as small 
molecule inhibitors (sunitinib, axitinib, pazopanib, van-
detanib, cabozantinib, sorafenib) that target VEGFR2 and 
other receptor tyrosine kinases [53].
Finally, there is emerging evidence that tumor resist-
ance occurs in cancer patients treated with conventional 
anti-vascular therapy. Several hypotheses to explain this 
resistance have been already proposed, and they include 
an increased redundancy of other angiogenic factors that 
compensate for the specific pathway blockade [54], the 
presence of a hypoxic microenvironment that modifies 
signaling pathways in both tumor and vasculature cells [55] 
and epigenetic mechanisms [56]. Moreover, bone marrow 
myeloid cells recruited by tumor-derived factors (TDF) 
play an important role in promoting and sustaining tumor 
angiogenesis/vasculogenesis and include Tie2-expressing 
monocytes, neutrophils and myeloid-derived suppressor 
cells (MDSC), generally defined as CD11b+Gr-1+ cells 
[57]. A role for CD11b+Gr1+ cells in tumor resistance to 
anti-VEGF antibody treatment was recently proposed by 
Ferrara et al. [58]. This effect depends on the up-regulated 
Fig. 2  Future development of CD248-targeting immunotherapy. 
Tumor-derived EPC/pericytes expressing CD248 antigen will be 
selectively eliminated by both active and passive immunotherapeutic 
approaches. The immune system of cancer patients can be educated 
to recognize the specific vascular antigen by several active immu-
notherapies such as DNA vaccines, based on fusing CD248 cDNA 
sequence with the cDNA of adjuvant molecules; peptide vaccines, 
in which the CD248 immunodominant peptide will be injected in 
association with specific adjuvants; and DC vaccines, in which syn-
geneic DC will be loaded with the immunodominant CD248 peptide 
and then injected into cancer patients. All or most of these strategies 
should be able to stimulate both an antibody- and cellular-mediated 
CD248-specific immune response. To overcome the immunosup-
pressive tumor microenvironment that limits the functionality of the 
immune response, resulting in protection of the transformed cells, 
the most successful clinical approach may likely be passive immuno-
therapy that, like a “Trojan horse,” transfers a large group of highly 
potent effector immune agents into the tumor-bearing host. These 
Trojan horses can be in the form of anti-CD248 antibodies, anti-
CD248 CAR T bodies or engineered high-affinity anti-CD248 T cells
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production and secretion of protein Bv8 (also known as 
prokineticin-2) by CD11b+Gr-1+ cells specifically induced 
by granulocyte colony-stimulating factor (G-CSF). Thus, 
G-CSF overproduction by tumors has a deleterious effect 
promoting vasculature alteration through a Bv8-dependent 
pathway that bypasses VEGF and renders tumors refrac-
tory to anti-VEGF therapy. Pharmacological/immunologi-
cal MDSC inhibitors are able to either inhibit MDSC dif-
ferentiation/maturation from precursors or inhibit MDSC 
accumulation in lymphoid organs [59] and can be used to 
synergize with CD248-targeting modalities. Moreover, as 
recently described in the literature, the accumulation of T 
regulatory lymphocytes (Treg) at tumor sites has been cor-
related with biomarkers of tumor-associated angiogenesis 
such as VEGF overexpression and increased microvessel 
density in endometrial [60] and breast cancers [61] pro-
viding clinical indication for an association between Treg 
and angiogenesis. Treg can contribute to tumor angiogen-
esis through both indirect and direct mechanisms. Treg 
sustain angiogenesis indirectly by eliminating effectors 
T lymphocytes that secrete angiostatic soluble molecules 
such as TNF-α, IFN-γ, CXCL9, CXCL10 and CXCL11. 
Moreover, Treg are able to directly promote angiogenesis 
in ovarian cancer by production of CCL28 that increases 
VEGF levels in the tumor microenvironment [62]. Deple-
tion of Treg significantly down-regulates VEGF expression 
in the tumor, and subsequently angiogenesis within tumor 
sites, and therefore favors an anti-tumor immune response. 
Immunological/pharmacological anti-Treg treatments 
include cyclophosphamide, gemcitabine, mitoxantrone, 
fludarabine, thalidomide analogues, cyclooxygenase 2 
inhibitors, as well as Denileukin diftitox (Ontak), a fusion 
protein of human IL-2 and diphtheria toxin, able to reduce 
the frequency of Treg in peripheral blood of chronic T cell 
lymphoma patients [63]. Combination treatment with any 
of the above anti-Treg treatments with a CD248-targeting 
strategy may form a complementary approach against the 
tumor vasculature network. Moreover, the CD248-targeting 
strategy can be used to treat non-cancer-related inflamma-
tory diseases such as arthritis; in fact, it has recently been 
reported that CD248 genetic deletion using Tem1−/− mice 
promotes osteoblast-mediated bone formation and reduces 
local inflammation [64]. In conclusion, our DNA-based 
immunotherapy approach targeting the tumor vasculature 
with a novel TVA demonstrates that CD248 can be targeted 
immunologically and generates potent anti-CD248 T cell 
responses as well as anti-tumor responses. Alternate thera-
peutic approaches targeting CD248 and other modalities in 
combination with CD248 targeting are warranted.
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